RCM 📈 R1 RCM - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7493971052
RCM: Revenue Cycle Management, Healthcare Technology, Financial Solutions
R1 RCM Inc. is a provider of technology-driven solutions designed to enhance the financial performance and patient experience of health systems, hospitals, and physician groups. By leveraging its operating partnership and end-to-end solutions, the company manages multiple aspects of the revenue cycle, enabling hospital and physician customers to realize significant financial leverage and revenue improvement. This comprehensive approach allows healthcare providers to streamline their revenue cycle operations, reduce costs, and improve overall efficiency.
In addition to its end-to-end solutions, R1 RCM Inc. offers a range of modular solutions tailored to meet the specific needs of hospital and physician group customers. These modular solutions include functional partnership, an outsourcing solution that targets specific revenue cycle areas for improvement; revenue recovery, a solution designed to fast-track payer and patient cash collections; revenue optimization, a solution that uncovers missed or underreported revenue; clinical integrity, a solution used to improve documentation and coding accuracy to maximize earned revenue for services provided; and regulatory navigation, a compliance-first solution that ensures government reimbursement accuracy, pharmacy savings, and compliance. By offering these modular solutions, R1 RCM Inc. provides healthcare providers with the flexibility to address specific revenue cycle challenges and improve their financial performance.
R1 RCM Inc. has a history dating back to 2003, when it was incorporated under the name Accretive Health, Inc. The company underwent a name change in January 2017, rebranding itself as R1 RCM Inc. Headquartered in Murray, Utah, R1 RCM Inc. has established itself as a leading provider of revenue cycle management solutions for the healthcare industry. As of November 19, 2024, the company was taken private, marking a significant development in its evolution. With its strong focus on technology-driven solutions and commitment to improving the financial performance and patient experience of healthcare providers, R1 RCM Inc. continues to play a vital role in the healthcare industry. The company's website can be found at https://www.r1rcm.com, and its common stock is listed under the ISIN US7493971052, classified under the GICS Sub Industry of Health Care Services.
Additional Sources for RCM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RCM Stock Overview
Market Cap in USD | 6,044m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2010-05-20 |
RCM Stock Ratings
Growth 5y | 43.6% |
Fundamental | 2.60% |
Dividend | - |
Rel. Strength Industry | 12866 |
Analysts | 3.08/5 |
Fair Price Momentum | 45.71 USD |
Fair Price DCF | 11.42 USD |
RCM Dividends
No Dividends PaidRCM Growth Ratios
Growth Correlation 3m | 98.6% |
Growth Correlation 12m | 85.3% |
Growth Correlation 5y | -24.6% |
CAGR 5y | 27.93% |
CAGR/Mean DD 5y | 0.82 |
Sharpe Ratio 12m | 1.08 |
Alpha | 274.54 |
Beta | 0.66 |
Volatility | 750.07% |
Current Volume | 0k |
Average Volume 20d | 3090.2k |
As of December 22, 2024, the stock is trading at USD 42.00 with a total of 1 shares traded.
Over the past week, the price has changed by -11.39%, over one month by -11.39%, over three months by +196.82% and over the past year by +302.30%.
Neither. Based on ValueRay Fundamental Analyses, R1 RCM is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.60 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RCM as of December 2024 is 45.71. This means that RCM is currently overvalued and has a potential downside of 8.83%.
R1 RCM has received a consensus analysts rating of 3.08. Therefor, it is recommend to hold RCM.
- Strong Buy: 0
- Buy: 1
- Hold: 11
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, RCM R1 RCM will be worth about 49.7 in December 2025. The stock is currently trading at 42.00. This means that the stock has a potential upside of +18.36%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 15.5 | -63.1% |
Analysts Target Price | 21.5 | -48.8% |
ValueRay Target Price | 49.7 | 18.4% |